OPRM1

Chr 6

opioid receptor mu 1

Also known as: LMOR, M-OR-1, MOP, MOR, MOR1, OPRM

This gene encodes one of at least three opioid receptors in humans; the mu opioid receptor (MOR). The MOR is the principal target of endogenous opioid peptides and opioid analgesic agents such as beta-endorphin and enkephalins. The MOR also has an important role in dependence to other drugs of abuse, such as nicotine, cocaine, and alcohol via its modulation of the dopamine system. The NM_001008503.2:c.118A>G allele has been associated with opioid and alcohol addiction and variations in pain sensitivity but evidence for it having a causal role is conflicting. Multiple transcript variants encoding different isoforms have been found for this gene. Though the canonical MOR belongs to the superfamily of 7-transmembrane-spanning G-protein-coupled receptors some isoforms of this gene have only 6 transmembrane domains. [provided by RefSeq, Oct 2013]

130
ClinVar variants
27
Pathogenic / LP
0.00
pLI score
8
Active trials
Clinical SummaryOPRM1
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
27 Pathogenic / Likely Pathogenic· 87 VUS of 130 total submissions
💊
Clinical Trials
8 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.31LOEUF
pLI 0.000
Z-score 0.53
OE 0.87 (0.591.31)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
-0.62Z-score
OE missense 1.10 (1.001.21)
311 obs / 281.8 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.87 (0.591.31)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.1.10 (1.001.21)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.06
01.21.6
LoF obs/exp: 17 / 19.5Missense obs/exp: 311 / 281.8Syn Z: -0.49

ClinVar Variant Classifications

130 submitted variants in ClinVar

Classification Summary

Pathogenic24
Likely Pathogenic3
VUS87
Likely Benign11
Benign5
24
Pathogenic
3
Likely Pathogenic
87
VUS
11
Likely Benign
5
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
24
0
24
Likely Pathogenic
0
0
3
0
3
VUS
0
83
4
0
87
Likely Benign
0
7
1
3
11
Benign
0
2
2
1
5
Total092344130

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

OPRM1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

📖
GeneReview available — OPRM1
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Pharmacogenomics of oxycodone: a narrative literature review.
Umukoro NN et al.·Pharmacogenomics
2021Review
The Role of Pharmacogenomics in Opioid Prescribing.
Wong AK et al.·Curr Treat Options Oncol
2022Review
Genetics of perioperative pain management.
Packiasabapathy S et al.·Curr Opin Anaesthesiol
2018Review
Pharmacogenetics in obstetric anesthesia.
Landau R et al.·Best Pract Res Clin Anaesthesiol
2017Review
Pharmacogenetics of Postoperative Nausea and Vomiting.
Aroke EN et al.·J Perianesth Nurs
2019Review
Pharmacogenomics of buprenorphine - a narrative review.
Aravindan L et al.·Pharmacogenomics
2025Review
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Opioid Use DisorderPregnancy Related

Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy

RECRUITING
NCT05942313Ilana HullStarted 2023-08-28
Buprenorphine/ Methadone exposure
AnalgesiaCardiac Surgery

Precision Analgesia for Cardiac Surgery

NOT YET RECRUITING
NCT05612399Kathirvel SubramaniamStarted 2026-04-01
PregnancyPostpartumChildbirth

HIIT vs MICT During Pregnancy and Health and Birth Outcomes in Mothers and Children

RECRUITING
NCT05009433Phase NAGdansk University of Physical Education and SportStarted 2021-06-24
High intensity interval training program for pregnant womenModerate intensity continuous training program for pregnant womenStandard obstetric care with extended education on healthy lifestyle
Stage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

ACTIVE NOT RECRUITING
NCT02754752Phase PHASE2M.D. Anderson Cancer CenterStarted 2016-09-13
Electroacupuncture TherapyElectroacupuncture TherapyLaboratory Biomarker Analysis
Opioid DependenceParentingInfant Development

Intervening With Opioid-Dependent MothersMothers and Infants

RECRUITING
NCT04454645Phase NAUniversity of DelawareStarted 2020-05-01
mABCmDEF
Fibromyalgia (FM)tDCSDuloxetine

Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM)

RECRUITING
NCT07203339Phase NAHospital de Clinicas de Porto AlegreStarted 2025-09-30
Transcranial direct current stimulation (tDCS) plus placebo.Duloxetine (60 mg) once dailyHome-based transcranial direct current stimulation
Paraphilic DisordersSexual AddictionParasomnia

Paraphilic Disorders and Other Conditions With Risk for Sexual Violence: a Case-control Study

RECRUITING
NCT05861752Region StockholmStarted 2022-10-19
Treatment as usual
PPAPSpine Fusion

Personalized Perioperative Analgesia Platform (PPAP) for Pediatric Spine Fusion Surgery (sIRB)

RECRUITING
NCT05367609Phase NASenthil SadhasivamStarted 2022-09-20
Preoperative Genotyping